Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971–84.

PubMed  Article  Google Scholar 

Garbe C. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5–24.

CAS  PubMed  PubMed Central  Article  Google Scholar 

American Cancer Society. Cancer facts & figures 2020. https://www.cancer.org/research/cancer-facts-statistics.html 2020.

Bruni JG. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Disco. 2019;18:197–218.

Article  CAS  Google Scholar 

Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30.

CAS  PubMed  Article  Google Scholar 

Wang P, Yuan Y, Lin W, Zhong H, Xu K, Qi X. Roles of sphingosine-1-phosphate signaling in cancer. Cancer Cell Int. 2019;19:295.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Nakajima M, Nagahashi M, Rashid OM, Takabe K, Wakai T. The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications. Tumor Biol. 2017;39. https://doi.org/10.1177/1010428317699133.

Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004;206:169–80.

CAS  PubMed  Article  Google Scholar 

Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharm. 2010;3:53–65.

CAS  Article  Google Scholar 

Newton J, Lima S, Maceyka M, Spiegel S. Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res. 2015;333:195–200.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Van Brooklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005;64:695–705.

Article  Google Scholar 

Ruckhäberle E, Rody A, Engels K, Gaetje R, Von Minckwitz G, Schiffmann S, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008;112:41–52.

PubMed  Article  CAS  Google Scholar 

Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, et al. Immunohistochemical distribution of sphinqosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem. 2005;53:1159–66.

CAS  PubMed  Article  Google Scholar 

Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008;14:6996–7003.

CAS  PubMed  Article  Google Scholar 

French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003;63:5962–9.

CAS  PubMed  Google Scholar 

Xu CY, Liu SQ, Qin MB, Zhuge CF, Qin L, Qin N, et al. SphK1 modulates cell migration and EMT-related marker expression by regulating the expression of p-FAK in colorectal cancer cells. Int J Mol Med. 2017;39:1277–84.

CAS  PubMed  Article  Google Scholar 

Liang W, Xie Z, Cui W, Guo Y, Xu L, Wu J, et al. Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer. J Cancer Res Clin Oncol. 2017;143:601–11.

CAS  PubMed  Article  Google Scholar 

Dickson MA, Carvajal RD, Jr AHM, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011;17:2484–92.

Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, et al. SPHK1 is a novel target of metformin in ovarian cancer. Mol Cancer Res. 2019;17:870–81.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Su L, Tian J, Sun J, Han N, Feng L, Yu B, et al. Lentivirus-mediated siRNA knockdown of SPHK1 inhibits proliferation and tumorigenesis of neuroblastoma. Onco Targets Ther. 2018;11:7187–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12:1479–86.

CAS  PubMed  Article  Google Scholar 

Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113:207–19.

CAS  PubMed  Article  Google Scholar 

Chu H, Chen X, Wang H, Du Y, Wang Y, Zang W, et al. MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumor Biol. 2014;35:3487–94.

CAS  Article  Google Scholar 

Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, et al. Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013;8:1.

CAS  Article  Google Scholar 

Li H, Sun L, Xu Y, Li Z, Luo W, Tang Z, et al. Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. PLoS One. 2013;8. https://doi.org/10.1371/journal.pone.0066679.

Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:1–19.

Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl J Med. 2012;366:2443–54.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hampton T. The Cancer Genome Atlas pan-cancer analysis project. Jama. 2006;296:1958.

CAS  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–62.

CAS  PubMed  Article  Google Scholar 

Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci. 2020;7. https://doi.org/10.1002/advs.201902880.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zheng X, Li W, Ren L, Liu J, Pang X, Chen X, et al. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy. Pharm Ther. 2019;195:85–99.

CAS  Article  Google Scholar 

Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, et al. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharm Ther. 2020;207:107464.

CAS  Article  Google Scholar 

Hänzelmann S, Castelo R, Guinney J GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14. https://doi.org/10.1186/1471-2105-14-7.

Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:1–10.

CAS  Article  Google Scholar 

Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:1–26.

Article  CAS  Google Scholar 

Kelsey C, Martin Mhatre V, Ho J-AL. Death by a thousand cuts: granzyme pathways of programmed cell death. Bone. 2012;23:1–7.

Google Scholar 

Pham CTN, Ley TJ. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin Immunol. 1997;9:127–33.

CAS  PubMed  Article  Google Scholar 

Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998;10:581–7.

CAS  PubMed  Article  Google Scholar 

Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22:265–8.

CAS  PubMed  Article  Google Scholar 

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7.

CAS  PubMed  Article  Google Scholar 

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (80-). 2001;291:319–22.

CAS  Article  Google Scholar 

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–51.